Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC

References

• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• JannePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• CrowleyEDi NicolantonioFLoupakisFBardelliALiquid biopsy: monitoring cancer-genetics in the bloodNat Rev Clin Oncol201310847248423836314
   PubMed Web of Science ®Google Scholar
• SheikineYRangachariDMcDonaldDCEGFR testing in advanced non-small-cell lung cancer, a mini-reviewClin Lung Cancer201617648349227381270
   PubMed Web of Science ®Google Scholar
• SundaresanTKSequistLVHeymachJVDetection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analysesClin Cancer Res20162251103111026446944
   PubMed Web of Science ®Google Scholar
• YanagitaMRedigAJPaweletzCPA prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trialClin Cancer Res201622246010602027281561
   PubMed Web of Science ®Google Scholar
• TakahamaTSakaiKTakedaMDetection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)Oncotarget2016736584925849927542267
   PubMed Web of Science ®Google Scholar
• OxnardGRThressKSAldenRSAssociation between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancerJ Clin Oncol201634283375338227354477
   PubMed Web of Science ®Google Scholar
• NormannoNDenisMGThressKSRatcliffeMReckMGuide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerOncotarget201787125011251627980215
   PubMedGoogle Scholar
• TanDSYomSSTsaoMSThe International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016J Thorac Oncol201611794696327229180
   PubMed Web of Science ®Google Scholar
• SacherAGPaweletzCDahlbergSEProspective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancerJAMA Oncol2016281014102227055085
   PubMed Web of Science ®Google Scholar
• ZhengDYeXZhangMZPlasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistanceSci Rep201662091326867973
   PubMed Web of Science ®Google Scholar
• LeeJYQingXXiuminWLongitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Oncotarget2016766984699326755650
   PubMed Web of Science ®Google Scholar
• Sueoka-AraganeNKatakamiNSatouchiMMonitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational studyCancer Sci2016107216216726577492
   PubMed Web of Science ®Google Scholar
• ChabonJJSimmonsADLovejoyAFCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNat Commun201671181527283993
   PubMed Web of Science ®Google Scholar
• Ortiz-CuaranSSchefflerMPlenkerDHeterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitorsClin Cancer Res201622194837484727252416
   PubMed Web of Science ®Google Scholar
• LuoJShenLZhengDDiagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysisSci Rep20144626925201768
   PubMed Web of Science ®Google Scholar
• ThressKSBrantRCarrTHEGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291Lung Cancer201590350951526494259
   PubMed Web of Science ®Google Scholar
• SekiYFujiwaraYKohnoTPicoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitorsOncologist201621215616426768482
   PubMed Web of Science ®Google Scholar
• ChaiXRenPWeiBA comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinomaClin Chim Acta201645710611127071701
   PubMed Web of Science ®Google Scholar
• ReckMHagiwaraKHanBctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: The ASSESS StudyJ Thorac Oncol201611101682168927468938
   PubMed Web of Science ®Google Scholar
• MokTSWuYLAhnMJOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancerN Engl J Med2017376762964027959700
   PubMed Web of Science ®Google Scholar
• ChiaPLDoHMoreyAMitchellPDobrovicAJohnTTemporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatmentLung Cancer201698293227393503
   PubMed Web of Science ®Google Scholar
• AiBLiuHHuangYPengPCirculating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancerOncotarget2016728445834459527323821
   PubMedGoogle Scholar
• ZhuYJZhangHBLiuYHEstimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIsOncotarget201788131951320528061461
   PubMedGoogle Scholar